Google's AMIE matches primary-care doctors in live video consults

verifiedHealthcare

Thursday, August 13, 2026

Confidence

High · — primary research with full study design; simulated-setting caveat is explicit

Evidence

Google Research + arXiv paper

Google Research published a randomized study in which AMIE (Video) matched or exceeded 10 board-certified primary care physicians across diagnosis, reasoning, and communication in simulated real-time video consultations.

The details

100 scenarios, 300 consultations, 15 patient actors; AMIE scored 83% vs. 68% for PCPs.
Google says real-patient studies must follow before clinical use conclusions.

What it means

Simulated actors and OSCE rubrics aren't clinical outcomes, but the first credible video-consult parity study from a major lab moves FDA and payer conversations from "if" to "under what evidence." Reimbursement, per story 05, is the next binding constraint.

100 scenarios, 300 consultations, 15 patient actors; AMIE scored 83% vs. 68% for PCPs.
Google says real-patient studies must follow before clinical use conclusions.

Sources

Apply this today

The hands-on layer the brief points to: a workflow you can run, a tool to test, and today’s 60-second video.

Workflow of the day

Turn a Raw Financial Model Into an AI-Native Analyst Brief: A Prompt Workflow

Finance · tested · saves 45-90 min per brief

Full walkthrough →

Tool watch

NVIDIA NeMo Switchyard

NVIDIA NeMo Switchyard: model routing as a real primitive, or a pre-alpha wrapper?

Read the breakdown →

In this issue

← Back to brief

Get the next one in your inbox

One daily brief. Every story gets a hype verdict.

No spam. Unsubscribe anytime.

On this page

The details
What it means

In this issue

← Back to brief

Stat of the Day

$2T▲

Anthropic implied IPO valuation

Investors' target for the October debut — more than double the May $965B private mark, and larger than SpaceX's record public float. Source

Today’s Take

Two Anthropic capital events, a coding-agent re-raise, a clinical-AI parity study, and a reimbursement warning — the through-line is that the money is moving in weeks and the evidence base is moving in years. The Decart deal is the tell: even the lab investors want to price at $2T is buying inference efficiency at a 50% premium because it can't build fast enough. Watch the S-1 when the quiet period lifts — it will settle whether the private-market math survives audited numbers, and whether the AMIE and NTAP fights are being fought over a market that's already been priced. Considered and passed: River AI's $1.1B seed (Tier-2 sourced, two-month-old company, "open-source personal AI" claim untested) and the OpenAI enterprise adoption report (vendor as its own analyst; no independent methodology).

— Agentic desk

Never miss a signal

Join professionals getting the daily AI brief every weekday morning.

No spam · Unsubscribe anytime

No sponsored verdicts
Sources linked
Corrections public